Pandey Vivek, Madi Sandesh, Gupta Pawan
Sports Injury and Arthroscopy Division, Orthopaedics, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Stempeutics Research Pvt. Ltd, Manipal Hospital, Whitefield, Banaglore, 560048, India.
J Clin Orthop Trauma. 2022 Feb 9;26:101804. doi: 10.1016/j.jcot.2022.101804. eCollection 2022 Mar.
Mesenchymal stromal cells (MSCs) express a wide range of properties anticipated to be beneficial for treating genetic, mechanical, and age-related degeneration in diseases such as osteoarthritis (OA). Although contemporary conservative management of OA is successful in many patients with mild-moderate OA, it often fails to improve symptoms in many patients who are not a candidate for any surgical management. Further, existing conservative treatment strategies do not prevent the progression of the disease and therefore fail to provide a long-term pain-free life. On the other hand, tremendous progress has been taking place in the exciting field of regenerative medicine involving MSCs (autologous and allogeneic), with promising translation taking place from basic science to the bedside. In this review, we comprehensively discuss the potential role of MSCs in treating OA, both autologous and off-the-shelf, allogeneic stem cells. Further, newer therapies are in the offing to treat OA, such as exosomes and growth factors.
间充质基质细胞（MSCs）具有多种特性，预计对治疗骨关节炎（OA）等疾病中的遗传、机械和年龄相关退变有益。尽管当代对OA的保守治疗在许多轻度至中度OA患者中取得了成功，但在许多不适合任何手术治疗的患者中，往往无法改善症状。此外，现有的保守治疗策略无法阻止疾病的进展，因此无法提供长期无痛的生活。另一方面，涉及MSCs（自体和异体）的再生医学这一令人兴奋的领域正在取得巨大进展，从基础科学到临床应用都有很有前景的转化。在这篇综述中，我们全面讨论了MSCs在治疗OA中的潜在作用，包括自体和现成的异体干细胞。此外，治疗OA的新疗法如外泌体和生长因子也即将出现。
